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Epstein-Barr virus (EBV) is a gamma herpesvirus that causes a life-long latent infection in human hosts. The
latent gene products LMP1, LMP2A and EBNA1 are expressed by EBV-associated tumors and peptide
epitopes derived from these can be targeted by CD8 Cytotoxic T-Lymphocyte (CTL) lines. Whilst
CTL-basedmethodologies can be utilized to infer the presence of specific latent epitopes, they do not allow a
direct visualization or quantitation of these epitopes. Here, we describe the characterization of three
TCR-like monoclonal antibodies (mAbs) targeting the latent epitopes LMP1125–133, LMP2A426–434 or
EBNA1562–570 in association with HLA-A0201. These are employed to map the expression hierarchy of
endogenously generated EBV epitopes. The dominance of EBNA1562–570 in association with HLA-A0201
was consistently observed in cell lines and EBV-associated tumor biopsies. These data highlight the
discordance between MHC-epitope density and frequencies of associated CTL with implications for
cell-based immunotherapies and/or vaccines for EBV-associated disease.
E
BV is a persistent herpesvirus acquired as a predominantly asymptomatic infection during childhood in
most human communities1. The virus can infect cells of both lymphoid and epithelial origin and its latent
infection phase is associated with malignancies that arise from these cell types, including Non-Hodgkin’s
lymphoma, Hodgkin’s Lymphoma2 and undifferentiated nasopharyngeal carcinoma (NPC)3. EBV latent gene
products found in tumors include Epstein-Barr Virus Nuclear Antigen 1 (EBNA1) and/or Latent Membrane
Protein 2A (LMP2A) and/or LatentMembrane Protein 1 (LMP1) depending upon the latency program employed
by the virus1,2. Despite the subdominant frequencies of CTLs specific for epitopes derived from these latent gene
products (0.05%–1%), they are implicated in the control of EBV infection in vivo1. The presence of these gene
products in the majority of EBV-associated tumors suggests that an analysis of their associated CTL epitopes is
essential for the design of immuno-targeting approaches including adoptive T-cell therapy.
The expression of EBV-latent epitopes in infected cells has been inferred indirectly from studies employing
CTLs, HLA tetramer analysis, and targeted lysis by T-cell lines1. Notably however, T-cell functionality is pivotal
for these analyses, and antigen specific CTLs can be rendered dysfunctional by viral immune evasion mechan-
isms4. A direct measure of HLA-peptide epitopes would circumvent this problem.
The direct analysis of surface EBV latency epitopes presented on MHC class I can be determined using mass
spectrometry but this is highly dependent on their hydrophobicity and ionization potential5.
An optimal approach is to develop antibodies that recognize viral epitopes in association with MHC6.
Termed TCR-like mAbs, these reagents exhibit high affinities and enable direct visualization and quantifica-
tion of the specific epitope presented7. In this study, antibodies targeting epitopes of EBV latent gene
products (LMP1125–133, LMP2A426–434 and EBNA1562–570) were generated and characterized. This allowed
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including flow cytometry, immunohistochemical staining, and
confocal microscopy. We next established the epitope expression
hierarchy amongst the three latent epitopes in cell lines and clin-
ically relevant EBV-associated tumor biopsies. Our observations of
this hierarchy and its differential binding on strain-associated
epitope variants have important implications for diagnosis,
immuno-targeting and vaccine development.
Results
Generation of high affinity TCR-like mAbs with exquisite speci-
ficity. In this report, we highlight an adaptation of conventional
hybridoma technology that enabled the production of high-affinity
TCR-like mAbs targeting three EBV latent epitopes displayed on
HLA-A0201. The methodology is illustrated in Supplementary
Information (Supplementary Fig. S1). Briefly, membrane-free
HLA-A0201 associated with EBV latent peptides (EBNA1562–570:
FMVFLQTHI; LMP1125–133: YLLEMLWRL; LMP2A426–434: CLGG-
LLTMV) were generated to immunize mice using an established
protocol8–11. The splenocytes of immunized mice were immuno-
magnetically selected prior to fusion. It is only with this enri-
chment that hybridomas producing TCR-like mAbs targeting
EBNA1562–570 and LMP2A426–434 in association with HLA-A0201
can be generated (Fig. 1a). For hybridomas producing antibodies
targeting LMP1125–133 in association with HLA-A0201, there is an
increase in the percentage of such hybridomas isolated following
splenocytes enrichment. The optimal representative monoclonal
hybridoma for each target was selected for subsequent analyses.
The binding specificities of these antibodies were examined using
flow cytometric analysis of T2 cells pulsed with 12 different HLA-
A0201 restricted peptides. The mAbs exhibited exquisite specificity
for their respective target peptide and not other HLA-A0201
restricted epitopes from a variety of human pathogens (Fig. 1b).
To determine the binding affinities of the three antibodies, surface
plasmon resonance (SPR) was employed. All three mAbs exhibited
strong binding affinities for their respective ligands (anti-HLA-A02/
EBNA1562–570 KD 5 6.02 nM; anti-HLA-A02/LMP1125–133 KD 5
1.85 nM; anti-HLA-A02/LMP2A426–434 KD 5 6.98 nM) (Fig. 1c).
To further examine the specificity of each TCR-like mAb in com-
parison to specific CTL, we determined their ability to inhibit CTL
lysis. The three mAbs inhibited the activity of their respective CTLs
in a specific dose-dependent manner, as shown by the inhibition of
CTL-inflected 51Cr release from target cells (Fig. 1d). Thus, we can
infer a degree of overlap in the targeting of TCRs and TCR-likemAbs
for the same viral epitopes. With these mAbs endowed with TCR
specificity, we can visualize and quantitate the expression profile of
latent EBV epitopes in infected cells.
Epitope variants are differentially recognized by respective TCR-
like mAbs. A factor that impacts upon epitope presentation is strain
differences in the encoding sequence of the latent antigens that
translates to CTL epitope variants. The classical methodology of
EBV typing does not adequately distinguish the pathogenic/tumo-
rigenic nature of various virus strains12. This typing does not give due
consideration to the clinical diversity of EBNA1, LMP1, and LMP2A,
which are the only three latent genes observed in associated
malignancies1. Using alternative classifications that were adopted
for each of these genes, we investigated the presentation of clinical
epitope variants9–11. Each of these epitope variants was pulsed onto
HLA-A0201 homozygous B cell lymphoblastoid cell lines for flow
cytometric analysis using the three TCR-like mAbs (Fig. 1e). Anti-
HLA-A02/EBNA1562–570 antibody can bind the B95-8 and Raji
variants. Anti-HLA-A02/LMP1125–133 antibody exhibited good
binding activity for B95-8 and Mediterranean (Med) variants but
none was observed for cells pulsed with the China1 variant-the
form of EBV that is linked to NPC10. Strong binding was observed
for anti-HLA-A02/LMP2A426–434 antibody for both the B95-8 and
the NPC variants. With the exception of the LMP1 (China1) variant,
our TCR-like mAbs can recognize the clinical variants of our
epitopes of interest (Fig. 1e). Together, these findings indicate that
epitopes associated with HLA-A0201 on infected cells are differen-
tially presented and this can be influenced by mutations associated
with strain variation.
Mapping the expression hierarchy of three latent epitopes on EBV
infected cells. We next analyzed the endogenous expression of
EBNA1562–570, LMP1125–133 and LMP2A426–434 epitopes on three
HLA-A0201 EBV-infected tumor cell lines of lymphoid and
epithelial origins: CCRF-SB, RPMI-6666 and C666-1A213. The
epitope variant of each cell line was determined by sequencing
their associated EBV virus (Fig. 2a). A flow cytometry based bead-
calibration kit, QIFIKITH (Dako), allowed the quantitation of the
three EBV latent peptides presented by HLA-A0201 (Supple-
mentary Fig. S2). This enabled us to map the ligand density and
expression hierarchy amongst the three latent EBV epitopes in the
cell lines (Fig. 2b). HLA-A0201/EBNA1562–570 complexes were
strongly expressed by the RPMI-6666 and CCRF-SB cell lines
(1500 6 61 and 2050 6 112 complexes respectively). An
intermediate level of expression was observed on the C666-1A2
cell line (590 6 144.3 complexes). In contrast, HLA-A0201/
LMP1125–133 and/LMP2A426–434 complexes exhibited relatively
intermediate or weak expression on CCRF-SB (437 6 127 and 668
6 66 complexes respectively) and RPMI-6666 (208 6 22 and 280 6
59 complexes respectively) and negligible complexes on C666-1A2.
This represents the first analysis of an expression hierarchy of HLA-
A0201/peptide complexes of latent EBV antigens. Surprisingly, the
high expression and dominance of HLA-A0201/EBNA1562–570 com-
plexes was consistent for all cell lines tested. With the exception for
the LMP1 (China1) variant of C666-1A2, our mAbs could bind the
variants of each epitope. This was consistent with our previous data
on binding of epitope variants (Fig. 1e).
The mAbs were also utilized to determine the cellular localization
and relative expression of the 3 latent EBV HLA-A0201/peptide
complexes by confocal microscopy. A high degree of surface local-
ization of the HLA-A0201/EBNA1562–570 complexes was observed in
all three cell lines (Supplementary Fig. S4) and the staining intensities
of the three latent antigens correlated with the quantitation data
shown in Figure 2b. In all cases, expression of HLA-A0201/EBNA-
1562–570 complexes on the surface of the tumor cells was stronger
than/LMP-1125–133 or/LMP-2A426–434. Our observations cannot be
ascribed to the presence or absence of the latent proteins from which
the epitopes were derived, as indicated by RT-PCR and immunoblot
(Figure 2c). The absence of an LMP1 immunoblot for C666-1A2 was
due to the mutations in the LMP1 (China1) variant that altered the
binding site for the anti-LMP1 antibody used13.
Detection of latent viral epitope expression in a humanized EBV
mouse model. To analyze the expression of the three antigens in the
context of a natural EBV infection, we employed an EBV-infected
humanized NOD/SCID/IL2rcnull (Hu-NSG) mouse model based on
reported protocols14. The latency program exhibited by these mice
was type III and thus the same as that observed in lymphopro-
liferative disorders in immuno-compromised patients1.
A schematic of our experimental approach is provided (Fig. 3a).
Following hematopoietic stem cells (HSC) reconstitution in NSG
mice and infection with EBV, the spleens were harvested for stain-
ing. Immunofluorescence staining was carried out using R-
Phycoerythrin (PE) conjugated TCR-like mAbs (Fig. 3b). Due to
the haplotype specific nature of our mAbs, only mice engrafted with
HLA-A0201HSC exhibited staining for all three complexes (Fig. 3b).
Thus, these staining validated the employment of our TCR-like
mAbs for epitope presentation studies in EBV-infected Hu-NSG
mouse model.
www.nature.com/scientificreports
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Dominance of EBNA1562–570 epitope expression in EBV-tumor
biopsies. To determine the clinical relevance of our observations,
cryo-sections of HLA-A0201 EBV-positive NPC biopsies were
stained with the respective TCR-like mAbs. EBV infected cells in
these biopsies stained strongly for HLA-A0201/EBNA1562–570
complexes and weakly for HLA-A0201/LMP2A426–434 complexes.
Sections were also stained with BB7.2 to determine their expres-
sion of HLA-A02 molecules. A representative data set (from 5
patients) is shown (Fig. 3c). The staining intensity correlated with
that observed in the NPC cell line C666-1A2 (Supplementary Fig.
S3). The LMP1125–133 complex staining was not observed due to
epitope mutation in the EBV NPC-linked China1 strain, corre-
lating with the data in Figure 1e.
Discussion
TCR-like mAbs are valuable reagents for direct epitope visualization
and detection. Several studies had illustrated its usefulness in epitope
discovery15, epitope processing16, and immuno-targeting17. However,
the numbers of documented antibodies are limited.
Previous reports documenting the generation of these mAbs used
either classical hybridoma fusion following murine immunization or
phage display methodologies. These resulted in antibodies that are
relatively low in affinity18 and stain poorly for endogenously gener-
ated epitopes19.
By enriching for immunized splenocytes prior to fusion, we
increased the number of hybridomas producing antibodies targeting





















































































































































































Figure 1 | Summary of TCR-like mAbs screened and characterization of TCR-like mAbs. (a) Summary of hybridomas isolated for each of the TCR-like
mAbs with andwithout prior enrichment for specific splenocytes prior to fusion. (b) Fine binding specificity of the TCR-likemAbs to T2 cells pulsed with
the EBNA1562–570 (purple histogram), LMP1125–133 (red), LMP2A426–434 (brown), Influenza A M158–66 (dark green), Mycobacterium tuberculosis
Ag85B143–152 (pink), HBV sAg183–191 (light blue), HIVPol476–484 (blue), gp120120–128 (yellow), Gag77–85 (grey), CMV IE1316–324 (orange), IE181–89(black),
pp65495–503 (light brown) or unpulsed cells (light green).(c) Affinity determination of the TCR-like mAbs using surface plasmon resonance by flowing
various concentrations of respective HLA-A0201/peptide complexes over CM5 chip-bound TCR-like mAbs. (d) Inhibition of specific lysis by specific
CTL using respective TCR-like mAbs at concentrations of 0.1 mg/ml, 1 mg/ml and 10 mg/ml. Error bars are standard deviation from average of three
independent experiments: **p, 0.01,***p, 0.005.(e) Differential recognition of the TCR-like mAbs against respective variants of epitopes pulsed on
HLA-A0201 positive BLCLs. Blue histogram denotes staining with murine isotype antibody MOPC1.
www.nature.com/scientificreports
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enrichment approach that hybridomas producing two of our TCR-
like mAbs targeting EBNA1 and LMP2A could be isolated.
Futhermore, our antibodies exhibit high specificity for their respect-
ive epitopes and binding affinity in the nanomolar range. Our data
validates this approach for isolating such rare hybridomas5 that are
technically challenging to generate20,21.
The high affinity and exquisite specificity of these reagents enabled
us to examine epitope variants presented on HLA-A0201 BLCLs.
These epitopemutations are due to viral sequence variation observed
in each of the latent EBV genes (LMP1, LMP2A and EBNA1). Our
antibodies bind to the epitope variants with differential activity sug-
gesting that the associated amino acid substitutions impact upon
presentation. Given that B95-8 is the only GMP-grade EBV strain
employed for the expansion of specific CTL for adoptive immu-
notherapy, our data indicate that more attention must be paid to
the EBV strain infecting the patient to ensure in vivo efficacy of
the adoptively transferred T- cells.
Staining for endogenously produced epitopes/peptides is a major
challenge for TCR-like mAbs19. Therefore, it was necessary to invest-
igate the binding ability of our mAbs for its respective endogenously
generated cognate peptide/MHC. As observed, our reagents enabled
the visualization of intracellular and extracellular localization of
endogenously generated epitopes. These reagents were also used to
visualize latent EBV epitope expressing cells in an EBV-infected
humanized mouse model. Coupled with QIFIKITH, we also quanti-
tated the density of endogenously generated epitopes in these three
EBV infected cell lines. A distinct epitope expression hierarchy was
consistently observed for all three cell lines with the dominance of
EBNA1562–570 over the other two epitopes analyzed. This was simi-
larly observed in clinically relevant EBV-associated NPC biopsies.
The dominance of EBNA1562–570 epitope did not correlate with the
reported frequency of the respective specific CTLs22 where CTLs
targeting LMP2A426–434 are dominant over the other two epitopes
(EBNA1562–570 and LMP1125–133).
Previous reports have intimated that EBNA1 inhibits its own pro-
cessing and presentation23. However, epitope expression can be
inferred from the presence of EBNA1 specific CTLs-this has been
proposed as evidence for dendritic cells cross-presentation of EBNA1
peptides24. Despite such indications, we are the first to directly visu-
alize and detect HLA-A0201/EBNA1562–570 complex expression in
infected cells of both hematopoietic and non-hematopoietic origin.
This suggests that EBNA1 can be processed and presented through
Figure 2 | Expression hierarchy of latent EBV epitopes in infected HLA-A0201 cell lines. (a) Epitope comparison amongst the variants and those
observed in the 3 cell lines studied. Red letters denote amino acid mutation. (b) Quantitation of HLA-A0201/LMP1,/LMP2A and/EBNA1 on CCRF-SB,
RPMI-6666 and C666-1A2 using TCR-like mAbs based on flow cytometry. Error bars are standard deviation from an average of three independent
experiments. **p, 0.01. n.d. denotes not detectable. (c) LMP1, LMP2A and EBNA1 in each of the cell lines was determined using RT-PCR andWestern
blot. b-actin was used as control. The blots and gels were cropped from full-length blots/gels presented in Supplementary Figure S3.
www.nature.com/scientificreports
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the classical MHC class I pathway. Although the presentation of
HLA-A0201/EBNA-1562–570 was reported to be low or non-existent
in previous reports employing CTL lines21,25,26, we were able to
directly detect this ‘‘rare’’ epitope in relatively high numbers. This
discordance could be due to dysfunctional CTLs4 or suggest that the
density of peptide-MHC complexes is not necessarily the key factor
in CTL selection and/or dominance. The immunodominance of
CTLs can be affected by an interplay of cellular andmolecular factors
such as CTL precursor frequencies27, quality of TCR-peptide-MHC
signaling potency28 and the relative binding affinity of the peptide
epitope for its associatedMHCmolecule29. These components and in
vivo tumormicroenvironment4 can influence both the scale and form
of the CTL response but were not addressed as part of this study.
In summary, by employing TCR-like mAbs, we have determined
the expression hierarchy of EBV latent antigens. Our data indicates
that EBNA1562–570 and LMP2A426–434 are possible biomarkers of
EBV-associated tumors in HLA-A0201 patients. The dominance of
EBNA1562–570 amongst the three epitopes was validated in cell lines
and ex vivo staining of clinical NPC biopsies. This observation has
important implications for both immunotherapy and EBV vaccine
development.
Methods
Cell lines. The cell lines RPMI-6666 (CCL-113, Hodgkin’s lymphoma), CCRF-SB
(CCL-120, acute lymphoblastic leukemia) and T2 (CRL-1992, TAP negative
lymphoblast) were obtained from theAmerican Tissue Culture Collection. C666-1A2
is aNPC cell line13 transduced withHLA-A0201 haplotype. The B cell lymphoblastoid
cell lines were generated from donors.
Antibody and peptide.TheHLA-A02-restricted peptides Epstein-Barr virus EBNA1
(B95-8)562–570 (FMVFLQTHI), EBNA1 Raji variant (FIVFLQTHI), LMP1 (B95-
8)125–133 (YLLEMLWRL), LMP1 China1 variant (YFLEILWRL), Med variant
(YLLEILWRL), LMP2A(B95-8)426–434 (CLGGLLTMV), LMP2A NPC variant
(SLGGLLTMV), Mycobacterium tuberculosis Ag85B143–152 (FIYAGSLSAL),
Hepatitis B virus sAg183–191 (FLLTRILTI), HIV Pol476–484 (ILKEPVHGV),
gp120120–128 (KLTPLCVTL), Gag77–85 (SLYNTIAVL), CMV IE1316–324
(VLEETSVML), IE181–89 (VLAELVKQI), pp65495–503 (NLPVMVATV) and
Influenza A virus M158–66 (GILGFVFTL) were synthesized by Mimotopes to 95%
purity and was analyzed by electrospraymass spectrometry. Themurine IgG1 isotype
control antibodyMOPC 21was purchased from Sigma-Aldrich. The rabbit anti-beta-
2 microglobulin polyclonal antibody and horseradish-peroxidase-conjugated goat
anti-mouse IgG were purchased from Thermo Fisher Scientific. CS1-4 antibody
cocktail (anti-EBV LMP1 antibody) and PE-conjugated goat anti-mouse IgG (H1 L)
were purchased from Dako. Alexa FluorH 488-conjugated goat anti-mouse IgG (H 1
L) antibodies were purchased from Invitrogen. 14B7 (anti-EBV LMP2 antibody) and
E1-2.5 (anti-EBV EBNA1 antibody) were purchased from Abd Serotec. Anti-human
CD20 antibody was purchased from Abcam.
Surface plasmon resonance (SPR). Kinetic studies were evaluated by surface
plasmon resonance using a BIAcore 3000TM (GE Healthcare). The monoclonal
antibodies were immobilized covalently onto the surface of sensor chip CM5 by
amine coupling. To determine the dissociation constant (KD) of the antibodies, the
respective MHC class I/peptide were flowed at different concentrations ranging from
320 nM to 10 nM over the relevant wells at a rate of 30 mL min21 at 25uC. Responses
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Figure 3 | Generation of Hu-NSG mice EBV model and staining of infected mouse spleen and clinical NPC biopsies with TCR-like mAbs.
(a) Experimental workflow of the Hu-NSGmice EBVmodel -isolation of HSC; injection into NSGmice; flow cytometric analysis of reconstitution; EBV
infection ofHu-NSGmice; and development of splenic lesions. The reconsitution of theHu-NSGmice with human immune cells was approximately 65%
6 3.9%. (b) Spleens of EBV infected HLA-A0201 Hu-NSGmice showed positive red staining for TCR-like mAbs specific to LMP1, LMP2A and EBNA1
binding. Scale bars, 50 mm. (c) Immunological staining of NPC biopsy. Control panel was stained with secondary antibody. BB7.2 antibody stained for
HLA-A02. The other two panels were stained with anti-HLA-A0201/LMP2A and anti-HLA-A0201/EBNA1 mAb. Positive staining was observed to be
reddish brown. Scale bars, 25 mm.
www.nature.com/scientificreports
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Western blot. CCRF-SB, RPMI666, and C666-1A2 cells were cultured in 100 mm
dishes and lysed with 13 RIPA buffer (Thermo Fisher Scientific) supplemented with
protease inhibitors (Roche Applied Science). The lysates were boiled for 15 min and
separated by 10% SDS-polyacrylamide gel electrophoresis, and transferred onto
polyvinylidene difluoride membrane (GE Healthcare) overnight. The membranes
were probed with CS1-4 antibody cocktail (anti-EBV LMP1 antibody) (152000
dilution) (Dako), 14B7 (anti-EBV LMP2A antibody) (155000 dilution) (AbD
Serotec) or E1-2.5 (anti-EBV EBNA1 antibody) (155000 dilution) (AbD Serotec).
The membranes were subsequently incubated with horseradish-peroxidase-
conjugated goat anti-mouse IgG or goat anti-rat IgG (Thermo Fisher Scientific). The
proteins were detected with enhanced chemiluminescence reagent (Western
Lightning ECL kit, Perkin Elmer).
Detection of LMP1, LMP2A and EBNA1 transcripts by RT-PCR. RNA from 1 3
106 cells was extracted using High Pure RNA Isolation kit (Roche Diagnostics) and
1 mg of total RNA was amplified by RT-PCR with OneStep RT-PCR kit (Qiagen)
using the appropriate primers as previously reported30. Beta actin was used as an
internal control.
Quantitation assays. Epstein-Barr virus infected HLA-A02 cells were stained with
the various TCR-like mAb followed by PE-conjugated goat-anti-mouse IgG
(Dako). The level of fluorescence intensity was compared with that of calibrated
beads containing pre-determined quantity of mouse monoclonal antibody per
bead (QIFIKITH calibration beads; Dako). By means of a standard curve based
upon the calibration beads, the number of complexes on the cell surface was
determined from the fluorescence intensity of each TCR-like monoclonal
antibody.
Raising of specific CTL lines. The HLA-A0201 restricted CTL specific for peptides
of Epstein-Barr associated proteins – LMP1125–133 (YLLEMLWRL), LMP2A426–434
(CLGGLLTMV) or EBNA1562–570 (FMVFLQTHI) was prepared. CD81 T cells
were isolated from a healthy HLA-A0201 positive donor. Human peripheral blood
mononuclear cells (PBMC) were isolated from fresh heparinized blood from
healthy donor by Ficoll-Paque density gradient centrifugation and CD81 T cells
were subsequently isolated using MACs isolation of CD81 positive T cells
(Miltenyi Biotec) in AIM H V media supplemented with 2% human AB serum.
These isolated CD8 T cells were specifically expanded by adding it into wells
seeded with 1 mM of LMP1125–133 (YLLEMLWRL), LMP2A426–434
(CLGGLLTMV) or EBNA1562–570 (FMVFLQTHI) peptides pulsed irradiated
PBMC feeder cells and incubated at 37uC in a CO2 incubator. On day 2 after
isolation, the media of the wells were supplemented with 20 U/ml IL2 to expand
specific peptide stimulated CD81 T cells. On day 10, CTLs were cloned by
limiting dilution assay and expanded in AIM H V media supplemented with 2%
AB serum, 20 U/ml IL2, 5 ng/ml IL7 and 100 pg/ml IL12 (R&D Systems) at a
density of 500,000 cells/well in 96-well plates seeded with irradiated PBMC feeder
cells pulsed with 1 mM of respective specific peptides.
Confocal microscopy. RPMI-6666 and CCRF-SB were seeded onto poly-L-lysine
coated glass coverslips while C666-1A2 was seeded overnight on glass coverslips
before fixing with methanol-acetone solution. The fixative was quenched with
PBS-10 mM glycine before staining was carried out using the respective TCR-like
mAbs or rabbit anti-beta-2-microglobulin polyclonal antibody (Thermo Fisher
Scientific). Staining was performed in a humidity chamber for 1 h in
permeabilization buffer with the concentrations of antibody at 151000 dilutions.
The coverslips were subsequently stained with either PE-conjugated goat anti-
mouse IgG (H 1 L) (Dako) or Alexa FluorH 647-conjugated goat anti-rabbit IgG
(H 1 L) (Invitrogen) with DAPI. ProLong Gold Antifade reagent (Invitrogen) was
used to mount the slides prior to analysis with a Leica TCS SP5 confocal
microsystems (Leica Microsystems) using the HCX PLAPO 63 3 objective
(numerical aperture: 1.4) The images were acquired at a resolution of 1024 3
1024 pixels for each set.
Flow cytometry. Approximately 5 3 105 cells were incubated with mAbs for 1 h at
4uC. After washing with 1 3 PBS, the cells were incubated with Alexa FluorH 488-
conjugated goat anti-mouse IgG (H1 L) (Invitrogen) for 30 min at 4uC. The samples
were assessed with FACSCalibur and analyzed using Cell Quest software (BD
Biosciences).
Chromium-release cytotoxic assay. 3 3 105 C1R-A2 cells were incubated with
50 mCi 51Cr (Perkin Elmer) in 100 ml culture medium, with or without the
relevant peptide (5 mM) for 1 h at 37uC, and plated in 96-well culture plates
(3,000 cells per well). HLA-A02 restricted epitope specific CTL lines were then
incubated for 3.5 h in 200 ml culture medium at an E/T ratio of 1051. Supernatant
was harvested from each well and transferred onto a lumaplate (Perkin Elmer) for
analysis with a TopCount NXT (Perkin Elmer). The percentage of release was
calculated using the formula:
average of sample release~spontaneous release=total release spontaneous releaseð Þ|100
TCR-like mAb staining of Hu-NSG mouse tissues. Spleens were harvested from
EBV-infected Hu-NSG mice and frozen in OCT medium. Tissue cryosections were
subsequently prepared on poly-L-lysine coated slides. The sections were fixed and
incubated with anti-human and anti-mouse FcR blocking agents (Miltenyi Biotec) to
prevent non-specific binding of the antibodies. The tissues were stained with PE-
conjugated TCR-like mAbs for 2 h. After washing, each slide was coated with DAPI
containing SlowFade Gold solution (Invitrogen). The slides were scanned and viewed
with MiraxViewer 1.12 software (Carl Zeiss).
Immunohistochemistry. Frozen NPC biopsies were sectioned (4 mm) and
embedded onto slides. Slides were fixed and subsequently stained with TCR-like
mAbs or BB7.231. Peroxidase block (Dako) was used prior to treatment with Dako
labeled polymer. After further washing, immunoperoxidase staining was developed
with DAB (Dako).
Animal experiments. BALB/c and NOD/SCID/IL2rcnull (NSG) mice were housed in
appropriate facilities. All experiments were approved by the IACUC of the National
University of Singapore and conducted in accordance with the Guide for the Care and
Use of Laboratory Animals (IACUC no: 027/07 and 106/10).
Biopsy and blood collection. Informed consent from healthy volunteers and patients
were taken before biopsy or blood extraction. NPC patients at theNational University
Hospital were enrolled with informed consent. The Institutional Review Board of the
hospital approved this study (IRB no: 07-043E).
Statistical analysis. Empirical data were analyzed using GraphPad Prism, version 5.0.
1-way ANOVA with Bonferroni post-test.
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